T. Rowe Price Associates’s Alexion Pharmaceuticals ALXN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
|
|||||
|
2021
Q2 | $133M | Sell |
|
|||||
|
2021
Q1 | $121M | Sell |
|
|||||
|
2020
Q4 | $240M | Sell |
|
|||||
|
2020
Q3 | $357M | Sell |
|
|||||
|
2020
Q2 | $835M | Sell |
|
|||||
|
2020
Q1 | $767M | Sell |
|
|||||
|
2019
Q4 | $1.31B | Buy |
|
|||||
|
2019
Q3 | $1.16B | Sell |
|
|||||
|
2019
Q2 | $1.84B | Sell |
|
|||||
|
2019
Q1 | $1.91B | Sell |
|
|||||
|
2018
Q4 | $1.72B | Sell |
|
|||||
|
2018
Q3 | $2.9B | Sell |
|
|||||
|
2018
Q2 | $2.74B | Buy |
|
|||||
|
2018
Q1 | $2.32B | Sell |
|
|||||
|
2017
Q4 | $2.51B | Sell |
|
|||||
|
2017
Q3 | $3.13B | Sell |
|
|||||
|
2017
Q2 | $2.78B | Buy |
|
|||||
|
2017
Q1 | $2.34B | Sell |
|
|||||
|
2016
Q4 | $2.58B | Buy |
|
|||||
|
2016
Q3 | $2.37B | Sell |
|
|||||
|
2016
Q2 | $2.31B | Sell |
|
|||||
|
2016
Q1 | $3.93B | Sell |
|
|||||
|
2015
Q4 | $5.4B | Buy |
|
|||||
|
2015
Q3 | $4.37B | Buy |
|
|||||
|
2015
Q2 | $4.74B | Buy |
|
|||||
|
2015
Q1 | $3.83B | Buy |
|
|||||
|
2014
Q4 | $3.73B | Buy |
|
|||||
|
2014
Q3 | $3.27B | Buy |
|
|||||
|
2014
Q2 | $2.7B | Buy |
|
|||||
|
2014
Q1 | $2.35B | Buy |
|
|||||
|
2013
Q4 | $1.98B | Sell |
|
|||||
|
2013
Q3 | $1.8B | Sell |
|
|||||
|
2013
Q2 | $1.56B | Buy |
|